JP2010539477A - 切断配列とスペーサーを用いた共鳴エネルギー転移アッセイ - Google Patents
切断配列とスペーサーを用いた共鳴エネルギー転移アッセイ Download PDFInfo
- Publication number
- JP2010539477A JP2010539477A JP2010524831A JP2010524831A JP2010539477A JP 2010539477 A JP2010539477 A JP 2010539477A JP 2010524831 A JP2010524831 A JP 2010524831A JP 2010524831 A JP2010524831 A JP 2010524831A JP 2010539477 A JP2010539477 A JP 2010539477A
- Authority
- JP
- Japan
- Prior art keywords
- construct
- yfp
- cfp
- donor
- bont
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003776 cleavage reaction Methods 0.000 title claims abstract description 140
- 230000007017 scission Effects 0.000 title claims abstract description 140
- 125000006850 spacer group Chemical group 0.000 title claims abstract description 55
- 238000003556 assay Methods 0.000 title claims description 22
- 238000002165 resonance energy transfer Methods 0.000 title claims description 5
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 235
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims abstract description 224
- 239000012634 fragment Substances 0.000 claims abstract description 64
- 239000000758 substrate Substances 0.000 claims abstract description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 61
- 230000008878 coupling Effects 0.000 claims abstract description 20
- 238000010168 coupling process Methods 0.000 claims abstract description 20
- 238000005859 coupling reaction Methods 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 102000004169 proteins and genes Human genes 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 70
- 150000001413 amino acids Chemical class 0.000 claims description 40
- 238000012546 transfer Methods 0.000 claims description 24
- 102000000583 SNARE Proteins Human genes 0.000 claims description 23
- 108010041948 SNARE Proteins Proteins 0.000 claims description 23
- 230000035945 sensitivity Effects 0.000 claims description 19
- 230000007423 decrease Effects 0.000 claims description 17
- 108010021466 Mutant Proteins Proteins 0.000 claims description 8
- 102000008300 Mutant Proteins Human genes 0.000 claims description 8
- 230000007246 mechanism Effects 0.000 claims description 6
- 101710138657 Neurotoxin Proteins 0.000 claims description 3
- 239000002581 neurotoxin Substances 0.000 claims description 3
- 231100000618 neurotoxin Toxicity 0.000 claims description 3
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 abstract description 59
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 abstract description 59
- 108010005730 R-SNARE Proteins Proteins 0.000 abstract description 14
- 102000002215 Synaptobrevin Human genes 0.000 abstract description 13
- 108010010469 Qa-SNARE Proteins Proteins 0.000 abstract description 11
- 102000050389 Syntaxin Human genes 0.000 abstract description 10
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 204
- 239000003053 toxin Substances 0.000 description 110
- 231100000765 toxin Toxicity 0.000 description 110
- 108700012359 toxins Proteins 0.000 description 110
- 235000018102 proteins Nutrition 0.000 description 87
- 102100038567 Properdin Human genes 0.000 description 75
- 235000001014 amino acid Nutrition 0.000 description 32
- 230000000875 corresponding effect Effects 0.000 description 27
- 230000005284 excitation Effects 0.000 description 27
- 239000000523 sample Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 210000000170 cell membrane Anatomy 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- 239000005090 green fluorescent protein Substances 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 15
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 15
- 238000000295 emission spectrum Methods 0.000 description 15
- 229910052751 metal Inorganic materials 0.000 description 15
- 239000002184 metal Substances 0.000 description 15
- 125000000539 amino acid group Chemical group 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 238000012544 monitoring process Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 210000000172 cytosol Anatomy 0.000 description 11
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 108030001722 Tentoxilysin Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 102000034287 fluorescent proteins Human genes 0.000 description 8
- 108091006047 fluorescent proteins Proteins 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 238000003119 immunoblot Methods 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 102100036151 Synaptotagmin-2 Human genes 0.000 description 6
- 150000003862 amino acid derivatives Chemical class 0.000 description 6
- 238000000695 excitation spectrum Methods 0.000 description 6
- 229930186900 holotoxin Natural products 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 6
- 239000004365 Protease Substances 0.000 description 5
- 108010055445 Synaptotagmin II Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- -1 motif Proteins 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000001378 electrochemiluminescence detection Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007900 neurotoxin activity Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000007026 protein scission Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000007888 toxin activity Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000026792 palmitoylation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000002504 synaptic vesicle Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 101100272852 Clostridium botulinum (strain Langeland / NCTC 10281 / Type F) F gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 210000003737 chromaffin cell Anatomy 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 102000003137 synaptotagmin Human genes 0.000 description 2
- 108060008004 synaptotagmin Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000025487 vesicle localization Effects 0.000 description 2
- 238000001429 visible spectrum Methods 0.000 description 2
- YBNMDCCMCLUHBL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-pyren-1-ylbutanoate Chemical compound C=1C=C(C2=C34)C=CC3=CC=CC4=CC=C2C=1CCCC(=O)ON1C(=O)CCC1=O YBNMDCCMCLUHBL-UHFFFAOYSA-N 0.000 description 1
- GSIJNJVQPCUGSE-JTQLQIEISA-N (2s)-6-amino-2-(2,4-dinitroanilino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GSIJNJVQPCUGSE-JTQLQIEISA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- YJCCSLGGODRWKK-NSCUHMNNSA-N 4-Acetamido-4'-isothiocyanostilbene-2,2'-disulphonic acid Chemical class OS(=O)(=O)C1=CC(NC(=O)C)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YJCCSLGGODRWKK-NSCUHMNNSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FBZFLXJHAMMUQM-UHFFFAOYSA-N 5-[(2-acetamidoethyl)amino]naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCNC(=O)C)=CC=CC2=C1S(O)(=O)=O FBZFLXJHAMMUQM-UHFFFAOYSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- TXSWURLNYUQATR-UHFFFAOYSA-N 6-amino-2-(3-ethenylsulfonylphenyl)-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1C1=CC=CC(S(=O)(=O)C=C)=C1 TXSWURLNYUQATR-UHFFFAOYSA-N 0.000 description 1
- YALJZNKPECPZAS-UHFFFAOYSA-N 7-(diethylamino)-3-(4-isothiocyanatophenyl)-4-methylchromen-2-one Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C1=CC=C(N=C=S)C=C1 YALJZNKPECPZAS-UHFFFAOYSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- 101100317631 Aspergillus tubingensis xynA gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 1
- 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101100271445 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) atp9 gene Proteins 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 108700005088 Fungal Genes Proteins 0.000 description 1
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 description 1
- 102220566453 GDNF family receptor alpha-1_Y66F_mutation Human genes 0.000 description 1
- 102220566455 GDNF family receptor alpha-1_Y66W_mutation Human genes 0.000 description 1
- 101150108358 GLAA gene Proteins 0.000 description 1
- OPINTGHFESTVAX-BQBZGAKWSA-N Gln-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N OPINTGHFESTVAX-BQBZGAKWSA-N 0.000 description 1
- CLSDNFWKGFJIBZ-YUMQZZPRSA-N Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O CLSDNFWKGFJIBZ-YUMQZZPRSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100523604 Mus musculus Rassf5 gene Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 101100395023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-7 gene Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 101100310552 Rattus norvegicus Snap25 gene Proteins 0.000 description 1
- 101000652311 Rattus norvegicus Synaptosomal-associated protein 25 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710124561 Synaptotagmin-2 Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102220615016 Transcription elongation regulator 1_S65C_mutation Human genes 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- UIZLQMLDSWKZGC-UHFFFAOYSA-N cadmium helium Chemical compound [He].[Cd] UIZLQMLDSWKZGC-UHFFFAOYSA-N 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- KPBGWWXVWRSIAY-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-6-isothiocyanato-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=C(N=C=S)C=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 KPBGWWXVWRSIAY-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002409 microspectrofluorometry Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
- 102200089551 rs5030826 Human genes 0.000 description 1
- 102200089550 rs869025616 Human genes 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 101150077833 xlnA gene Proteins 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本発明の分野は、ボツリヌス毒素及び破傷風毒素に関連するプロテアーゼアッセイのための蛍光共鳴エネルギー転移である。
材料及び方法
バイオセンサーDNA構築物の構築:pECFP−YFPベクターを作製するために、EcoRI及びBamHI部位を用いて、YFPcDNA(Clontec)をpECFP−C1ベクター(Clontech)中に挿入した。PCRを使用し、XhoI及びEcoRI部位(CFPとYFP遺伝子の間にある。)を用いて、pECFP−YFPベクター中に、ラットsybIIのアミノ酸33から94をコードするcDNAを増幅して、細胞を形質移入するために使用することができるCFP−SybII−YFP(CFP−Syb (33−94)−YFPとも称される。)構築物を得た。同じ方法を使用して(但し、SNAP−25の残基141から206を使用)、構築物CFP−SNAP−25−YFP(CFP−SNAP−25(141−206)−YFPとも称される。)を構築した。リンカーとして完全長ラットSNAP−25Bを有する構築物(CFP−SNAP25FL−YFP)も作製した。細菌イー・コリを用いて組換えキメラタンパク質を精製するために、本発明者らは、NheI及びBamHI部位を用いて、pECFP−YFPベクターからCFP−Sybll−YFP遺伝子及びCFP−SNAP−25−YFP遺伝子をpTrc−his(Invitrogen)ベクター中にも移動した。
FRET法を用いてボツリヌス神経毒素プロテアーゼ活性をモニターするために、sybII又はSNAP−25断片を介してCFP及びYFPタンパク質を接続し、それぞれ、CFP−SybII−YFP及びCFP−SNAP−25−YFPと表記される(図1A)。距離が増加するにつれて指数関数的に低下するCFP−YFPエネルギー転移効率を最適化するために、完全長タンパク質の代わりに毒素基質の短い断片を使用した。しかしながら、標的タンパク質断片が短すぎるようになるにつれて、BoNTによる切断効率は著しく減少する。従って、完全長シナプトブレビンと同じBoNT/B、F及びTeNTによる切断速度を保持すると報告されているので、シナプトブレビン配列のアミノ酸33から96を含有する領域を使用した。同様に、構築物がBoNT/A及びEによってなお確実に認識及び切断され得るようにするために、SNAP−25の残基141から206を選択した。
300nMキメラタンパク質CFP−SybII−YFPを、キュベット中で50nMの予め還元されたBoNT/Bホロ毒素と混合した。BoNT/B(0、2、5、10、30、60分など)を添加した後の異なる時点で、発光スペクトルを収集した。各スキャンの終了時に、キュベットから試料の少量(30μL)を取り出し、SDS搭載緩衝液と混合した。その後、これらの試料をSDS−pageゲルに供し、組換えキメラタンパク質中のhis6タグに対する抗体を用いて、キメラタンパク質の切断を可視化した。図3Aに示されているように、BoNT/Bとのバイオセンサータンパク質の温置は、YFP発光の減少及びCFP発光の増加をもたらした。FRET比の減少は、BoNT/Bによるキメラタンパク質の切断の程度と合致している(図3A、下図)。この結果は、バイオセンサータンパク質の切断は、そのFRET比の変化を記録することによって、リアルタイムでモニターすることができることを示す。
上記実験は、それらの標的バイオセンサータンパク質の発光スペクトルの変化をモニタリングすることによって、ボツリヌス神経毒素の活性はインビトロで検出可能であることを示した。次いで、本発明者らは、マイクロプレートリーダーを用いて、リアルタイムでバイオセンサータンパク質の切断をモニターできるかどうかを決定した。これは、将来的な高処理量スクリーニングにこのアッセイを適合させるための可能性を示す。図4Aに示されているように、96ウェルプレート中で、300nMCFP−SNAP−25−YFPキメラタンパク質を10nMBoNT/Aと混合した。CFPを436nmで励起し、90分にわたって、30秒の間隔で、CFPチャネル(470nm)とYFPチャネル(527nm)の蛍光を記録した。BoNT/Aの添加は、YFPチャネル発光の減少及びCFPチャネル発光の増加をもたらした。この結果によって、本発明者らは、複数試料中のボツリヌス神経毒素酵素活性の速度論をリアルタイムで追跡することができた。例えば、図4Bに示されているように、BoNT/A又はEの様々な濃度を300nMCFP−SNAP−25−YFP中に添加し、図4Aに記載されているように、各試料のFRET比を同時にモニターした。FRET比の変化は毒素濃度と関連していた。毒素濃度が高いほど、FRET比の減少は迅速であった。CFP−SNAP−25−YFPのみ(図4C、左図)又はCFPとYFPの混合物(図4C、右図)の何れかに対して、著しい変化が検出されなかったので、FRET比のこの変化は特異的である。
CFP−YFPを基礎とするバイオセンサーアッセイは、インビトロでボツリヌス神経毒素を検出するために使用することができるのみならず、生きた細胞中でも使用することができる。この用途を確立するために、CFP−SNAP−25−YFPでPC12細胞を形質移入した。PC12細胞は、BoNT/A及びEを取り込むことができる神経内分泌細胞株である。形質移入された細胞をBoNT/A(50nM)とともに72時間温置し、CFP−YFPFRET検出に対する特殊なフィルターの組を備えた落射蛍光顕微鏡を用いて、CFP−SNAP25−YFPを発現する細胞のFRET比を記録した。簡潔に述べれば、2つのフィルターの組(1つはCFP用(励起437nm/発光470nm)及び他方はFRET用(励起437nm/発光535nm))を用いて収集された同じ細胞からの画像の蛍光強度間の比として、FRET比を計算する。合計53個の細胞を収集し、同じバイオセンサータンパク質を発現するが、毒素に曝露されなかった対照細胞の同じ数と比較した。図6Aに示されているように、72時間のBoNT/A処理は、検査されている細胞集団に対するFRET比を著しく減少させた(p<1.47E−05)。野生型PC12細胞は、BoNT/B及びFに対して感受性でない。
細胞を基礎とする研究を実施するために、本発明者らは、CFP−SNAP−25(141−206)−YFPセンサーでまずPC12細胞を形質移入した(図7a)。材料と方法の部に上述されているように、落射蛍光顕微鏡を用いた確立された3つ組みフィルター法を用いて、図2aに示されているように、生きた細胞中のFRETシグナルを取得した(Gordon, et al., Quantitative fluorescence resonance energy transfer measurements using fluorescence microscopy.BioPhys.J. 74, 2702−2713(1998);及びSorkin et al.,Interaction of EGF receptor and grb2 in living cells visualized by fluorescence resonance energy transfer(FRET) microscopy.Curr.Biol.10,1395−1398(2000))。形質移入されたPC12細胞を50nMBoNT/Aで96時間処理した。それらの蛍光画像を分析し、標準化されたFRET比(補正されたFRET/CFP)を図7bにプロットした。SNAP−25(41−206)断片は、インビトロで完全長SNAP−25と類似の毒素切断速度を有することが報告されたが(Washbourne et al., Botulinum neurotoxin types A and E require the SNARE motif in SNAP−25 for proteolysis.FEBS Lett.418, 1−5 (1997))、CFP−SNAP−25(141−206)−YFPは生きた細胞中では優れた毒素基質でないように見受けられた。96時間のBoNT/A(50nM)の温置は細胞集団間でのFRET比の小さな(但し、有意な)シフトを示し、細胞内では切断が非効率的であり、このセンサーは細胞内での毒素検出のためには実用的でないことを示唆する。
Claims (25)
- 構築物であって、
ドナーが双極子−双極子カップリング機構によってアクセプターにエネルギーを転移することができるような電気的カップリングを与えるように配置されたドナー標識及びアクセプター標識、並びに
ドナーとアクセプターの間に配置され、切断部位配列を有するリンカー、並びにドナーと切断部位配列及びアクセプターと切断部位配列の少なくとも1つの間のスペーサー、
を有する構築物。 - ドナー及びアクセプターの少なくとも1つが蛍光団又は発色団の少なくとも1つである、請求項1の構築物。
- 双極子−双極子カップリング機構がフォスター共鳴エネルギー転移(FRET)である、請求項1の構築物。
- リンカーが5nm以上の一次構造長を有する、請求項1の構築物。
- リンカーが8nm以上の一次構造長を有する、請求項1の構築物。
- リンカーが12nm以上の一次構造長を有する、請求項1の構築物。
- リンカーは少なくとも3つのアミノ酸を有するスペーサーを含む、請求項1の構築物。
- リンカーがSNAREモチーフを含む、請求項7の構築物。
- スペーサーが少なくとも5つのアミノ酸を有する、請求項7の構築物。
- スペーサーが(GGGGS)n(nは、1から3である。)を含む、請求項7の構築物。
- スペーサーが(EAAAK)n(nは、1から3である。)を含む、請求項7の構築物。
- スペーサーが、スペーサーなしの対応する構築物と比べて電気的カップリングを増加させる、請求項1の構築物。
- スペーサーがSNAREモチーフを含む、請求項1の構築物。
- 切断部位配列がSNAREタンパク質の変異タンパク質を含む、請求項1の構築物。
- 切断部位配列が(a)SNAREタンパク質、モチーフ、変異タンパク質の少なくとも1つ及び(b)少なくとも5つのアミノ酸を有するスペーサーを含む、請求項1の構築物。
- スペーサーが、(GGGGS)n及び(EAAAK)n(nは、1から3である。)からなる群から選択される配列を含む、請求項15の構築物。
- 構築物が、CFP−(SGLRSRA)−SNAP−25−(SNS)−YFP及びCFP−(SGLRSRA)−シナプトブレビン−(SNS)−YFPからなる群から選択される、請求項1の構築物。
- ドナー標識とアクセプター標識の間のエネルギー転移の感度を向上させる方法であって、
リンカーを通じて物理的に結合されたドナー標識とアクセプター標識を含む構築物を準備すること、
リンカー中に切断部位配列を含めること、及び
ドナーと切断部位配列並びにアクセプターと切断部位配列の少なくとも1つの間に、リンカー中にスペーサーを含めること(これによりドナーとアクセプター間の電気的カップリングが増加される。)、
を含む、方法。 - 構築物がタンパク質を基礎とする構築物であり、及びリンカーがペプチド配列である、請求項18の方法。
- 切断部位配列がSNAREタンパク質又はその断片若しくは変異タンパク質を含み、及びスペーサーが少なくとも5つのアミノ酸を含む、請求項18の方法。
- スペーサーが、(GGGGS)n及び(EAAAK)n(nは、1から3である。)からなる群から選択される配列を含む、請求項18の方法。
- スペーサーが、ドナーとアクセプターの間の三次構造距離を低下させることによって、ドナーとアクセプターの間の電気的カップリングを増加させる、請求項18の方法。
- スペーサーが、ドナーとアクセプター間に電気的跳躍を付与することによって、ドナーとアクセプターの間の電気的カップリングを増加させる、請求項18の方法。
- アッセイが完全な細胞に対して適用される、請求項18の方法。
- ボツリヌス神経毒素を検出する方法であって、a)請求項1の構築物を準備すること(リンカーは、検出されるべきボツリヌス神経毒素の基質タンパク質又は切断可能なその断片である。)、b)ボツリヌス神経毒素が基質タンパク質又はその断片を切断する条件下で、ボツリヌス神経毒素を含有すると疑われる試料に前記構築物を曝露すること、並びにc)構築物が試料に曝露される前及び後に、FRETシグナルを検出及び比較することを含み、FRETの減少が試料中のボツリヌス神経毒素の存在を示す、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97267307P | 2007-09-14 | 2007-09-14 | |
US60/972,673 | 2007-09-14 | ||
PCT/US2008/004252 WO2009035476A1 (en) | 2007-09-14 | 2008-03-31 | Resonance energy transfer assay with cleavage sequence and spacer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010539477A true JP2010539477A (ja) | 2010-12-16 |
JP5412689B2 JP5412689B2 (ja) | 2014-02-12 |
Family
ID=40452297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010524831A Active JP5412689B2 (ja) | 2007-09-14 | 2008-03-31 | 切断配列とスペーサーを用いた共鳴エネルギー転移アッセイ |
Country Status (9)
Country | Link |
---|---|
US (6) | US9303284B2 (ja) |
EP (1) | EP2208067B1 (ja) |
JP (1) | JP5412689B2 (ja) |
KR (1) | KR101226604B1 (ja) |
CN (2) | CN101932936B (ja) |
CA (1) | CA2699612C (ja) |
ES (1) | ES2717354T3 (ja) |
LT (1) | LT2208067T (ja) |
WO (1) | WO2009035476A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014518376A (ja) * | 2011-06-01 | 2014-07-28 | バイオマジソン・インコーポレイテッド | 非fretボツリヌスアッセイ |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7374896B2 (en) * | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
US8022172B2 (en) * | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
CN101932936B (zh) | 2007-09-14 | 2016-04-27 | 拜奥麦迪逊公司 | 利用切割序列和间隔子的共振能量转移测定 |
US10246492B2 (en) | 2009-10-16 | 2019-04-02 | Biomadison, Inc. | Botulinum assay with synaptobrevin substrate moiety |
ES2576747T3 (es) | 2009-10-16 | 2016-07-11 | Biomadison, Inc. | Ensayo de transferencia de energía de resonancia con un resto de sustrato de sinaptobrevina |
JP2013534415A (ja) * | 2010-06-11 | 2013-09-05 | シナプティック リサーチ,リミテッド ライアビリティ カンパニー | N末端ルール・プロテアーゼ同定方法及びその使用法 |
US9303285B2 (en) | 2012-01-04 | 2016-04-05 | Biomadison, Inc. | Methods and compounds for increasing sensitivity of botulinum assays |
US11325954B2 (en) | 2011-06-01 | 2022-05-10 | Biomadison, Inc. | Compositions and methods for stability testing of botulinum toxin |
US10908146B2 (en) | 2011-06-01 | 2021-02-02 | Biomadison, Inc. | Compositions and methods for improving sensitivity in cell based assays |
EP2734635A1 (en) | 2011-07-19 | 2014-05-28 | ETH Zürich | Means and methods for determining clostridial neurotoxins |
EP2800973B1 (en) * | 2012-01-04 | 2018-05-16 | Biomadison, Inc. | Methods and compounds for increasing sensitivity of botulinum assays |
GB2514825B (en) * | 2013-06-06 | 2017-11-08 | Bangor Univ | Sensors |
ES2818986T5 (es) | 2013-08-09 | 2024-01-25 | Biomadison Inc | Ensayo de toxina botulínica con sensibilidad mejorada |
PL405046A1 (pl) * | 2013-08-12 | 2015-02-16 | Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Pan | Genetycznie kodowany oparty na FRET biosensor aktywności MMP-9 i jego zastosowanie |
CA2923764C (en) | 2013-09-17 | 2020-09-29 | Mcmaster University | Method for assaying a protease |
US9365659B2 (en) * | 2014-01-29 | 2016-06-14 | Excelsior Nanotech Corporation | System and method for optimizing the efficiency of photo-polymerization |
WO2016079310A1 (en) * | 2014-11-21 | 2016-05-26 | Merz Pharma Gmbh & Co. Kgaa | Methods for the determination of the biological activities of neurotoxin polypeptides |
DE102015101668A1 (de) * | 2015-02-05 | 2016-08-11 | Benteler Automobiltechnik Gmbh | Zweifach fallendes Heiz- und Formwerkzeug sowie Verfahren zur Herstellung warmumgeformter und pressgehärteter Kraftfahrzeugbauteile |
US12019066B2 (en) * | 2016-05-16 | 2024-06-25 | Biomadison, Inc. | Assay with synaptobrevin based moiety |
CN106442969B (zh) * | 2016-08-23 | 2018-08-31 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种用于检测肉毒毒素的试剂盒 |
EP3438649B1 (en) * | 2017-07-31 | 2020-03-11 | Vestel Elektronik Sanayi ve Ticaret A.S. | Identification tag and method of identifying an object |
US20210181181A1 (en) * | 2017-12-15 | 2021-06-17 | The Regents Of The University Of Colorado, A Body Corporate | Synthetic Fluorescent Protein Biosensors and Use Thereof in Drug Screening Methods |
WO2020168061A1 (en) * | 2019-02-13 | 2020-08-20 | Biomadison, Inc. | Compositions and methods for protease screening |
TW202113072A (zh) * | 2019-06-07 | 2021-04-01 | 美商辛那皮克研究有限責任公司 | 基因工程化細胞 |
US20220326221A1 (en) * | 2019-08-13 | 2022-10-13 | Synaptic Research, Llc | Cells Highly Sensitive to Clostridial Neurotoxin |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006502378A (ja) * | 2002-09-27 | 2006-01-19 | アラーガン、インコーポレイテッド | クロストリジウム毒素に関する細胞ベースの蛍光共鳴エネルギー転移(fret)アッセイ |
US20070059316A1 (en) * | 2003-09-23 | 2007-03-15 | Pallenberg Alexander J | Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents |
WO2007047342A1 (en) * | 2005-10-12 | 2007-04-26 | Allergan, Inc. | Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret) |
JP2007520211A (ja) * | 2003-12-19 | 2007-07-26 | ウィスコンシン・アラムナイ・リサーチ・ファウンデイション | ボツリヌス神経毒素検出のための方法および複合体 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444879A (en) * | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
US6803188B1 (en) * | 1996-01-31 | 2004-10-12 | The Regents Of The University Of California | Tandem fluorescent protein constructs |
US5965699A (en) | 1996-11-06 | 1999-10-12 | The United States Of America As Represented By The Secretary Of The Army | Assay for the proteolytic activity of serotype a from clostridium botulinum |
WO2000023463A2 (en) * | 1998-10-16 | 2000-04-27 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent dye binding peptides |
US7374896B2 (en) * | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
US7208285B2 (en) | 2001-08-28 | 2007-04-24 | Allergan, Inc. | Fret protease assays for botulinum serotype A/E toxins |
US20080064054A1 (en) | 2001-08-28 | 2008-03-13 | Ester Fernandez-Salas | Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity |
US6504006B1 (en) | 2001-10-12 | 2003-01-07 | Nancy Rose Shine | Substrate peptides and assays for detecting and measuring proteolytic activity of serotype A neurotoxin from clostridium botulinum |
AU2003272800A1 (en) | 2002-10-01 | 2004-04-23 | University Of Maryland | Methods for identifying inhibitors of botulinum neurotoxins |
ATE442161T1 (de) | 2002-10-31 | 2009-09-15 | Wisconsin Alumni Res Found | Botulinumneurotoxin-b-rezeptoren und ihreverwendung |
US7337632B2 (en) | 2005-10-19 | 2008-03-04 | Findings Incorporated | Earring with floating decorative element |
ATE472612T1 (de) * | 2005-11-25 | 2010-07-15 | Hidex Oy | Homogener lumineszenz-bioassay |
DE602006016984D1 (de) * | 2005-12-12 | 2010-10-28 | Us Gov Health & Human Serv | Sonde zum sequenzieren von nukleinsäure und verwendungsverfahren |
CN101932936B (zh) * | 2007-09-14 | 2016-04-27 | 拜奥麦迪逊公司 | 利用切割序列和间隔子的共振能量转移测定 |
ES2576747T3 (es) | 2009-10-16 | 2016-07-11 | Biomadison, Inc. | Ensayo de transferencia de energía de resonancia con un resto de sustrato de sinaptobrevina |
-
2008
- 2008-03-31 CN CN200880115966.2A patent/CN101932936B/zh active Active
- 2008-03-31 WO PCT/US2008/004252 patent/WO2009035476A1/en active Application Filing
- 2008-03-31 CN CN201610223681.7A patent/CN105907718B/zh active Active
- 2008-03-31 JP JP2010524831A patent/JP5412689B2/ja active Active
- 2008-03-31 CA CA2699612A patent/CA2699612C/en active Active
- 2008-03-31 US US12/059,570 patent/US9303284B2/en active Active
- 2008-03-31 LT LTEP08742464.4T patent/LT2208067T/lt unknown
- 2008-03-31 EP EP08742464.4A patent/EP2208067B1/en active Active
- 2008-03-31 KR KR1020107007467A patent/KR101226604B1/ko active IP Right Grant
- 2008-03-31 ES ES08742464T patent/ES2717354T3/es active Active
-
2012
- 2012-09-24 US US13/625,723 patent/US8969016B2/en active Active
-
2015
- 2015-02-25 US US14/631,379 patent/US9249451B2/en active Active
-
2016
- 2016-03-08 US US15/064,379 patent/US9677113B2/en active Active
-
2017
- 2017-06-12 US US15/620,062 patent/US9988666B2/en active Active
-
2018
- 2018-05-15 US US15/980,454 patent/US10526637B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006502378A (ja) * | 2002-09-27 | 2006-01-19 | アラーガン、インコーポレイテッド | クロストリジウム毒素に関する細胞ベースの蛍光共鳴エネルギー転移(fret)アッセイ |
US20070059316A1 (en) * | 2003-09-23 | 2007-03-15 | Pallenberg Alexander J | Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents |
JP2007520211A (ja) * | 2003-12-19 | 2007-07-26 | ウィスコンシン・アラムナイ・リサーチ・ファウンデイション | ボツリヌス神経毒素検出のための方法および複合体 |
WO2007047342A1 (en) * | 2005-10-12 | 2007-04-26 | Allergan, Inc. | Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret) |
Non-Patent Citations (2)
Title |
---|
JPN5010011356; WATERHAUS: BIOCHEMISTRY V33 N8, 1994, P2121-2128 * |
JPN5010011358; MELTZER R: THE JOURNAL OF BIOLOGICAL CHEMISTRY V282 N35, 20070831, P25548-25559 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014518376A (ja) * | 2011-06-01 | 2014-07-28 | バイオマジソン・インコーポレイテッド | 非fretボツリヌスアッセイ |
JP2016039809A (ja) * | 2011-06-01 | 2016-03-24 | バイオマジソン・インコーポレイテッドBiomadison, Inc. | 非fretボツリヌスアッセイ |
Also Published As
Publication number | Publication date |
---|---|
US20110033866A1 (en) | 2011-02-10 |
ES2717354T3 (es) | 2019-06-20 |
US20180251812A1 (en) | 2018-09-06 |
KR101226604B1 (ko) | 2013-01-28 |
US9677113B2 (en) | 2017-06-13 |
KR20100080530A (ko) | 2010-07-08 |
CN105907718A (zh) | 2016-08-31 |
EP2208067A1 (en) | 2010-07-21 |
WO2009035476A1 (en) | 2009-03-19 |
US20170283851A1 (en) | 2017-10-05 |
US8969016B2 (en) | 2015-03-03 |
CA2699612A1 (en) | 2009-03-19 |
CN101932936B (zh) | 2016-04-27 |
CN105907718B (zh) | 2020-10-27 |
EP2208067B1 (en) | 2019-02-06 |
US10526637B2 (en) | 2020-01-07 |
US9303284B2 (en) | 2016-04-05 |
EP2208067A4 (en) | 2010-12-22 |
CN101932936A (zh) | 2010-12-29 |
US20160177369A1 (en) | 2016-06-23 |
JP5412689B2 (ja) | 2014-02-12 |
CA2699612C (en) | 2013-01-08 |
US20150176051A1 (en) | 2015-06-25 |
LT2208067T (lt) | 2019-03-12 |
US9988666B2 (en) | 2018-06-05 |
US20130095513A1 (en) | 2013-04-18 |
US9249451B2 (en) | 2016-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5412689B2 (ja) | 切断配列とスペーサーを用いた共鳴エネルギー転移アッセイ | |
US8137924B2 (en) | Method and compositions for detecting botulinum neurotoxin | |
KR101679370B1 (ko) | 비-fret 보툴리눔 검정법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110224 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110329 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130618 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130927 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131007 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20131024 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131024 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5412689 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |